JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuan, C.-S.
Right arrow Articles by Osinski, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, C.-S.
Right arrow Articles by Osinski, J.

Vol. 300, Issue 1, 118-123, January 2002

Effects of Subcutaneous Methylnaltrexone on Morphine-Induced Peripherally Mediated Side Effects: A Double-Blind Randomized Placebo-Controlled Trial

Chun-Su Yuan , Gang Wei , Joseph F. Foss , Michael O'Connor, Theodore Karrison and Joachim Osinski

Committee on Clinical Pharmacology (C-S.Y., G.W., J.F.F.), Department of Anesthesia and Critical Care (C-S.Y., G.W., J.F.F., M.O'C., J.O.), and Department of Health Studies (T.K.), University of Chicago, Chicago, Illinois

Methylnaltrexone, the first peripheral opioid receptor antagonist, has the potential to prevent or reverse opioid-induced peripherally mediated side effects without affecting analgesia. In previous human trials, we demonstrated that intravenous methylnaltrexone prevented morphine-induced delay in gastrointestinal transit time. We also observed that the compound decreased some of the morphine-induced troublesome subjective effects. However, the effects of subcutaneous methylnaltrexone, a more convenient route of administration, have not been evaluated. In this controlled trial, we evaluated the efficacy of subcutanous methylnaltrexone in antagonizing morphine-induced delay in oral-cecal transit time. In addition, opioid-induced unpleasant subjective effects and pharmacokinetics were studied. We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 ± 20.5 min to 155 ± 27.9 min (mean ± S.D., P < 0.01). After 0.1 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 110 ± 41.0 min. In the second group (n = 6), morphine increased the transit time from a baseline level of 98 ± 49.1 min to 140 ± 58.2 min (P < 0.01). After 0.3 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 108 ± 59.6 min (P < 0.05 compared with placebo plus morphine). In addition, subcutaneous methylnaltrexone significantly decreased morphine-induced subjective rating changes. Pharmacokinetic data after subcutaneous drug injection were compared to the data obtained from previous intravenous and oral administrations. Our results suggest that subcutaneous methylnaltrexone may have clinical utility in treating opioid-induced constipation and reducing opioid-induced unpleasant subjective symptoms.

0022-3565/02/3001-0118$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
D. W. Kemp and J. N. Brown
Recent Advances in Pharmacotherapy
Journal of Pharmacy Practice, October 1, 2009; 22(5): 446 - 466.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, S. Rus, D. S. Simpson, A. Wolf, T. E. Prisinzano, and M. J. Kreek
The Effects of Herkinorin, the First {micro}-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 154 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. Moss and C. E. Rosow
Development of Peripheral Opioid Antagonists: New Insights Into Opioid Effects
Mayo Clin. Proc., October 1, 2008; 83(10): 1116 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Thomas, S. Karver, G. A. Cooney, B. H. Chamberlain, C. K. Watt, N. E. Slatkin, N. Stambler, A. B. Kremer, and R. J. Israel
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
N. Engl. J. Med., May 29, 2008; 358(22): 2332 - 2343.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
L. E. Gomez-Martinez
Gestational Age Dependency in the Prenatal Toxicity and in the Disposition Kinetics of the Novel Anticonvulsant HEPP (D,L-3-Hydroxy-3-ethyl-3-phenylpropionamide) after Subcutaneous Administration in Pregnant Rats
International Journal of Toxicology, May 1, 2007; 26(3): 237 - 246.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
C.-S. Yuan, H. Doshan, M. R. Charney, M. O'Connor, T. Karrison, S. A. Maleckar, R. J. Israel, and J. Moss
Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans
J. Clin. Pharmacol., May 1, 2005; 45(5): 538 - 546.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, T. J. Harris, and M. J. Kreek
Antiallodynic Effects of Loperamide and Fentanyl against Topical Capsaicin-Induced Allodynia in Unanesthetized Primates
J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 155 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. J. Bates, J. F. Foss, and D. B. Murphy
Are Peripheral Opioid Antagonists the Solution to Opioid Side Effects?
Anesth. Analg., January 1, 2004; 98(1): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W.-Z. Ho, C.-J. Guo, C.-S. Yuan, S. D. Douglas, and J. Moss
Methylnaltrexone Antagonizes Opioid-Mediated Enhancement of HIV Infection of Human Blood Mononuclear Phagocytes
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1158 - 1162.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.